[Translation] A two-phase, prospective, observational study conducted in mainland China to compare the use and effectiveness of XGEVA®/Angavir® with ZOMETA® in preventing bone-related events in patients with solid tumor bone metastases
第1阶段:药物使用和安全性
描述XGEVA®/安加维®和ZOMETA®用于预防实体瘤(乳腺癌、前列腺癌或肺癌)继发骨转移患者发生骨骼相关事件(SRE)的使用;
描述不同骨靶向药物(BTA,XGEVA®/安加维®vs ZOMETA®)用于预防SRE在治疗起始阶段的患者预后因素的可比性;
描述在接受XGEVA®/安加维®治疗的患者中特别关注的不良事件(AESI)的发生率;
第2阶段:预防症状性SRE的有效性
描述XGEVA®/安加维®相对于ZOMETA®预防症状性SRE的有效性;
[Translation] Phase 1: Medication Use and Safety
To describe the use of XGEVA®/Angavir® and ZOMETA® for the prevention of skeletal-related events (SRE) in patients with bone metastases secondary to solid tumors (breast, prostate, or lung cancer);
To describe the comparability of patient prognostic factors at the initiation of treatment with different bone-targeted agents (BTA, XGEVA®/Angavir® vs ZOMETA®) for the prevention of SRE;
To describe the incidence of adverse events of special interest (AESI) in patients treated with XGEVA®/Angavir®;
Phase 2: Effectiveness in preventing symptomatic SRE
To describe the effectiveness of XGEVA®/Angavir® relative to ZOMETA® in preventing symptomatic SRE;